Overview:
While hematopoietic stem cell transplantation (HSCT) offers the potential for cure in many hematologic malignancies, patients undergoing allogeneic HSCT may experience graft-versus-host-disease (GVHD). However, standard immunosuppressive protocols may fail to control GVHD, leading to a poor outcome. A greater understanding of the underlying mechanisms of GVHD has led to the development of new approaches for GVHD prophylaxis, as well as addressing acute and chronic GVHD.
This program will bring together experts on GVHD to discuss best practices and emerging approaches for the prophylaxis and management of acute and chronic GVHD. Faculty will examine how patient and disease characteristics influence treatment decision-making. In addition, participants will have the opportunity to submit questions directly to the expert faculty.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Explain the rationale for new and emerging therapies for the prevention and treatment of acute and chronic GVHD
- Analyze efficacy and safety findings from clinical trials evaluating new and emerging therapies for the prevention and treatment of acute and chronic GVHD
- Implement recommended strategies for the prompt identification and management of treatment-related toxicities associated with GVHD prophylaxis and treatment
- Utilize evidence-based treatment guidelines to individualize GVHD prophylaxis and management
